In this week’s episode of The Spotlight Roundup, we spotlight Field Trip Health as they complete the largest financing raise ever for a psychedelic company in Canada; Red Light Holland completes the sale and import of psychedelic truffles into Canada; Mind Cure Health launches a product sales division; and we look at New York, which may be on the brink of a big psychedelic boom.
Hey guys! As Promised, we’re live streaming the MindMed (MMED / MMEDF ) Earnings Conference Call.
What we’re expecting to hear and discuss later is any clinical trial updates for MindMed, updates for Project Lucy and Project Layla and perhaps their potential Nasdaq Uplisitng !
I hope you guys found some value in this and I’ll keep you posted for more changes!
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://mindmed.co/news/press-release…
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #MindmedStock #MMEDNews
Powered by Restream https://restream.io/
Today is MindMed’s (MMED /MMEDF / MMQ) Conference call
#Mindmed #MMED #MindmedConferenceCall
Maya Health’s Co-Founder and CEO, David Champion, discusses the importance of data and analytics in the growing psychedelic community.
There were A LOT OF DEVELOPMENTS THIS WEEK, so strap on your seat belts and let’s dive into what happened this week with: MindMed ( MMED / MNMD / MMQ ), Compass Pathways (CMPS), NUMINUS (NUMI), Fieldtrip Health (FTRP / FTRPF), Mydecine ( MYCO / MYCOF), HAVN Labs
( HAVN / HAVLF), Novamind ( NM / NVMDF), Champignon Brands aka Braxia Scientific
(old ticker :SHRM / new ticker: BRAX / BRAXF), Nova Mentis (NOVA / NMLSF) and Small Pharma (DMT).
Timestamps:
0:00 – Intro
0:54 – MindMed’s (MMED / MNMD) Project Angie Announcement
1:47 – Compass Pathways (CMPS) Q1 Financial Results Date & Business Updates
3:16 – Analyst Coverage and Buy Ratings for CMPS
4:35 – Mydecine ( MYCO / MYCOF) 2020 Financial Results & Business Highlights
9:17 – Numinus Wellness (NUMI) Q2 Financial Results
11:25 – Field Trip Health (FTRP/ FTRPF) Opens more clinics
12:19 – Novamind ( NM / NVMDF) doubling its clinics
14:25 – Champignon Brands (SHRM /SHRMF) changing its named to Braxia Scientific (BRAX / BRAXF)
15:31 – NEW DMT company that began trading on may 6th under the name SMALL PHARMA ( DMT)
17:19 – HAVN Labs (HAVN) opens a new lab in Jamaica
17:50 – Nova Mentis launches a new clinical study using psilocybin to treat autism
Link to MindMed’s Project Angie Press release:
https://mindmed.co/news/press-release/mindmed-announces-project-angie-targeting-the-treatment-of-pain-with-psychedelics/
Link to Compass Pathways Q1 financial Results date:
https://ir.compasspathways.com/news-releases/news-release-details/compass-pathways-plc-announce-first-quarter-2021-financial
Link to Compass Pathways (CMPS) analyst ratings: https://www.marketbeat.com/stocks/NASDAQ/CMPS/price-target/
Link to Mydecine ( MYCO/ MYCOF) Full Year 2020 Financial results Plus business updates
https://www.globenewswire.com/news-release/2021/05/03/2221266/0/en/Mydecine-Reports-Full-Year-2020-Financial-Results-and-Provides-Business-Update.html
Link to Numinus (NUMI) Q2 2021 Financial Results:
https://www.newswire.ca/news-releases/numinus-wellness-q2-2021-results-highlighted-by-17-25-million-financing-mindspace-wellbeing-acquisition-and-clinical-trial-collaboration-with-maps-pbc-846735411.html
Link to Field Trip’s (FTPR / FTPRF) 7th Psychedelic-assisted therapy Clinic:
https://psilocybinalpha.com/news/field-trip-health-ltd-announces-opening-of-psychedelic-enhanced-therapy-center-in-houston-locations-of-next-5-field-trip-health-centers
Link to Novamind’s (NM / NVMDF) Ketamine Clinic article:
https://novamind.ca/2021-05-04-novamind-doubles-in-size-adds-four-new-psychedelic-mental-health-clinics/
Link to Champignon Brands ( SHRM/ SHRMF) announcing their name change to Braxia Scientific (BRAX / BRAXF):
https://thedeepdive.ca/champignon-brands-to-change-name-to-braxia-scientific/
Link to Small Pharma ( DMT):
https://psilocybinalpha.com/news/small-pharma-completes-reverse-take-over-transaction
Link to Havn’s (HAVN / HAVLF) Jamaica lab:
https://www.psychedelicfinance.com/articles/havn-labs-jamaica-facility-now-fully-operational
Link to Nova Mentis launching a clinical study to learn more about Autism:
https://psilocybinalpha.com/news/nova-mentis-launches-autism-clinical-study
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
editing by: @themyaholy
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #Numi #CMPS
In this interview, David Flores sits down with Dr. Mike…
What’s up psychedelic stocks investors?!? Today marked atai Life Science’s (Nasdaq: atai) first-ever conference call, for Quarter 2, 2021. In the conference call, atai Life Sciences gave updates on their varying projects, ranging from attempting to treat depression, to cognitive impairment associated with schizophrenia. They also give insights on atai’s digital medicines division and answer investor’s questions at the end of the call.
This Peter Thiel-backed psychedelic therapies company is fighting for the title of the most advanced psychedelic stock. With 10+ different projects under their belt, atai is one of the most exciting companies to keep an eye on in the industry.
This conference call can help investors answer the questions: is atai stock a good investment? Will atai go up? Are psychedelic stocks / shroom stocks good investments? Can psychedelics heal depression? Can psychedelics be used for mental health?
Enjoy the episode!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Check out our website: thepsychedelicinvestor.com
Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
#atai #ataiLifeSciences #PsychedelicStocks
![Compass Pathways Q4 Earnings Call Highlights [Is CMPS Closing In On MindMed?]](https://psychedelicspotlight.com/wp-content/uploads/2022/06/maxresdefault-47-600x338.jpeg)
Hey guys! I promised ya’ll that I will keep you updated on Compass Pathways (NASDAQ: CMPS) earnings call. There has been some pretty interesting developments on the company that I thought I should Bring to your attention. Compass Pathways is one of the psychedelic companies that is the furthest advanced in their clinical trials (Phase IIB to treat TRD). However, I wasn’t aware that they are doing a LOT more. This is quite interesting because in my opinion, CMPS is not a one trick pony anymore and it might as well be in direct competition with my favorite company in this sector (MindMed).
In this video, we’ll cover:
1. Compass Pathways’ Financials
2. Their IP
3. Therapists Training
4. Future Projects
5. Digital Technology
I hope that this is not going to enrage the MindMed fan boys out there. I just thought that it might be interesting for some of you psychedelic investors.
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media!
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://mindmed.co/wp-content/uploads/2020/11/investor-deck.pdf
https://www.businesswire.com/news/home/20190905005528/en/Usona-Institute-Clinical-Trial-Psilocybin-Major-Depressive
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#CompassPathways #CMPS #MindMed
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.
